Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Some investors like to get in early. You telling people whats what is in a telegram group is a story told again and again on lse and never without motive.
Yes they can. I warned people in the telegram group their heads were being filled with nonsense. Photos of a shed and some plumbing, ffs. Told them value was years away as it was a R&d phase. They all knew better and they've lost over two thirds of their investment since then.
No one can estimate a true value until we have obtained our commercial licence. I’m guessing this will be in the autumn after this summer’s harvest. Much will depend on independence or M&A
How's that guess work going for you?
280,012 bought by me today and again comes up as a sell.
There is continuous good news from the company every month - good long term investment - not worried about my substantial long term hold
Spread has moved up and down all morning, good oportunity to buy in. Directors took all share payments from ana.
I thought I'd have a quick purchase of a few more shares given the price, hopefully I do hope that there is more positive news with the company within the next couple of months
157,371 purchased this morning but gone through as a sell.
Melissa Sturgess, CEO, Ananda Developments
?
I think 2023 will see the European medical cannabis space continue to evolve in an active and dynamic way. It is clear we are past the point of no return in terms of medical cannabis across Europe, and it seems that in many jurisdictions we are reaching the same inflection point for recreational cannabis.
In particular I have a feeling we may see the UK space offer up something transformational, as we did in 2018 with medical cannabis legalisation. Most of us didn’t see that coming. We thought medical cannabis legalisation was still a couple of years away.
During the latter part of 2022 we have seen patient numbers increase; we have learned there is a desire for specialists to prescribe from their own practice rather than necessarily via a cannabis clinic; we have seen the MHRA make clear statements about the path to regulated UK-manufactured medical cannabis products, and we have seen the NHS make a clear request to its clinicians to report cannabis prescribing to its own registry.
Patients and advocacy groups are also well organised and working to maintain pressure to bring medical cannabis to patients who need it. I would not be surprised if we see a regulatory change in 2023 which helps to clear the path to making medical cannabis a better recognised, more readily prescribed medicine in the UK.
ANA is on the Aquis Exchange (AQSE).
Many brokers deal with Aquis, Hargreaves Lansdown for example does.
We’re done buy share ? Dnt see it on English market
No it's not being stopped. Go to its website and read its RNSs.
not sure of the facts but ,bbc look east[30/12/2022] had a report about a child whom suffers etc has been able to get a type of cannabis from his gp which stops all his problems ,but has just been told the supply will stop as the import etc from the far east[israel] has been stopped by hmgov ,and funding to supply etc has been withdrawn ,so what is going on ? is this co going to be stopped from going forward ? i suppose cannabis is for low life so must be stopped but single malt for gentry is ok to be funded for growth ,
I wonder if we will ever know the results of the voting for the inter family loan that has left shareholders out in the cold?
The ???? are 'thumbs up' emojis BTW.
System can't seem to handle emojis at LSE. I liked that update, it was good.
That's how you do an RNS.
????????
And right on que a nothing RNS to try brush over the robbery that took place yesterday. Pity the results of the voting couldn't be so detailed.
Charles Morgan Developements.
No surprises that this got pushed through at the Strugess family meeting but where is an actual break down of the voting as is the norm?
Is good, if you put it in a pharmaceutical context. Very quickly we will find ourselves in the throes of commercial licensing, I think. I'm a capitalist. I am happy for Charles to be richly rewarded when we are successful.
* Charles Morgan(husband of Melissa) taking shareholders to the cleaners with 'cheap' funding.
Progress
Ananda's ambition is to be a leading UK grower and manufacturer of consistent,
high-quality, carbon zero, medical cannabis for UK, and later international,
patients.
* In a significant step for the UK medical cannabis industry, on 16 November
2022, the Medicines and Healthcare products Regulatory Agency of the UK
Government (the MHRA) made an announcement clarifying the process for a
company to be authorised to grow and manufacture medical cannabis
commercially.
* The MHRA process involves a series of checks, inspections and validations
involving both the UK Home Office and the MHRA.
* Previously, there has been no formalised joint approach to medical cannabis
cultivation and manufacturing from the Home Office and the MHRA.
* The Directors believe that the proposals announced by the MHRA demonstrate
the UK Government's commitment to the development of a UK medical cannabis
cultivation and manufacturing industry.
* Ananda has always intended to apply for a commercial medical cannabis
growing licence and is well positioned to take advantage of this latest
move by the UK government:
+ The MHRA's five step process assumes a company is starting with no Home
Office Controlled Drug Licence or operations. Ananda already has a
Controlled Drug Licence and has conducted one full season of field
trial growing. The Directors expect that this will expedite Ananda's
progress through the licensing process.
+ Ananda has already commenced workstreams for the GACP/GMP/GDP* facility
within its existing Home Office Licenced Research Facility in
Lincolnshire.
* Ananda's field trials of its single crop, natural season growing in
Lincolnshire have proven its strategy is the right one. The Directors
believe that no artificial light or heat is the best environment in which
to grow superior medical cannabis flower and that the low cost of this
growing method is key for financial success.
Ananda's CEO Melissa Sturgess commented: "We see this announcement from the
MHRA as the most significant step for the UK medical cannabis industry since
legalisation of medical cannabis in 2018. To see a joined-up approach from the
Home Office and the MHRA is extremely welcome, and we believe it demonstrates
strong acknowledgement and support for this nascent industry. We have been
working diligently towards commercial operations since 2019 and are perfectly
positioned to act on this announcement from the MHRA. We have already
conducted field trials on 13 strains of cannabis, effectively giving us a head
start down the regulatory pathway. We have already built a large research
facility and are using the learnings from our operational work to inform GMP
facility planning. And, most importantly, we have a small, dedicated team of
best in class professionals to make it happen.
No small anount of money either. They must be confident on gov approval being nailed on to commit to all shares payment.